The following is a summary of “Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity,” published in the ...

ANSWER: Heart failure is simply when the heart is unable to pump all the blood it needs to meet the body’s demands. Heart ...

The EF is normally 50% to 75%, so heart failure with an EF of less than 50% is heart failure with reduced ejection fraction ...

In infants with cardiomyopathy-associated chronic HF, baseline LVEF of less than 40% and β blocker use indicate a decreased chance of LVEF normalization.

My husband is 73 and was diagnosed with heart failure and a severely dilated left ventricle. At the time, he was pumping 10 ...

My husband is 73 and was diagnosed with heart failure and a severely dilated left ventricle. At the time, he was pumping 10 liters per minute. He had a proBNP natriuretic peptide level over 10,000 and ...

CORXEL (formerly Ji Xing) acquired the rights to develop and commercialize aficamten in Greater China (including the Chinese mainland, Hong Kong SAR and Macau SAR, and Taiwan) from Cytokinetics in ...

Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights ...

Industry-First Capabilities Combined: Medera’s Novoheart has a unique human-based mini-Heart technology platform for disease modelling and drug screening with a track record of supporting FDA IND and ...

Researchers suggest an application to FDA may be made within the next 12 months, requesting approval to carry out a human clinical trial with the gene therapy.

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, ...

Innovation installed by AstraZeneca for advancing human heart-based R&D for investigational cardiovascular therapiesFeatures improved ...